(PDF 4 MB) Additional file 2: Table S1: Differential expression of miRNAs between primary gastric cancer and the corresponding metastatic tissue as determined by miRNA expression profile analysis. (DOC 41 KB) Additional file 3: Table S2: miRNA mimics and inhibitors used in this study. (DOC 31 KB) References 1. Wang J, Yu JC, Kang WM, Ma ZQ: Treatment strategy for early gastric cancer. Surg Oncol 2012, 21:119–123.PubMedCrossRef 2. Ferlay J, Shin HR, Bray F, LY2874455 concentration Forman D, Mathers C, Parkin DM: Estimates of
worldwide GDC-941 burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893–2917.PubMedCrossRef 3. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137–2150.PubMedCrossRef 4. Kim DW, Park SA, Kim CG: Detecting the recurrence of gastric cancer after curative resection: comparison of FDG PET/CT and contrast-enhanced abdominal CT. J Korean Med Sci 2011, 26:875–880.PubMedCrossRef 5. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA: Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer
2006, Mizoribine datasheet 107:2576–2580.PubMedCrossRef 6. Wienholds E, Plasterk RH: MicroRNA function in animal development. FEBS Lett 2005, 579:5911–5922.PubMedCrossRef 7. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116:281–297.PubMedCrossRef 8. Zhao X, Yang L, Hu J: Down-regulation of miR-27a might inhibit proliferation and drug resistance selleck kinase inhibitor of gastric cancer cells. J Exp Clin Cancer Res 2011, 30:55.PubMedCrossRef 9. Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007, 26:293–300.PubMedCrossRef 10. Ma RM, Jiang T, Kang XX: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Canc Res 2012, 31:38.CrossRef 11. Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, et al.: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012, 7:e41629.PubMedCrossRef 12. Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW, Wong N, Yu J, Cheng AS, To KF: Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012, 7:e33919.PubMedCrossRef 13. Xu Y, Sun J, Xu J, Li Q, Guo Y, Zhang Q: miR-21 is a promising novel biomarker for lymph node metastasis in patients with gastric cancer. Gastroenterol Res Pract 2012, 2012:640168.PubMed 14. Wang M, Li C, Nie H, Lv X, Qu Y, Yu B, Su L, Li J, Chen X, Ju J, et al.: Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett 2012, 586:2382–2388.